MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
RadNet Book Value 2011-2026 | RDNT
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value RadNet
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.13 B | 813 M | 491 M | 346 M | 258 M | 233 M | 200 M | 69.9 M | 52.1 M | 36.5 M | 7.7 M | 2.21 M | -2 M | -69.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.13 B | -69.8 M | 255 M |
Quarterly Book Value RadNet
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.31 B | 1.18 B | 1.13 B | 1.12 B | 1.09 B | 813 M | 796 M | 761 M | 493 M | 491 M | 458 M | 451 M | 421 M | 346 M | 339 M | 299 M | 281 M | 258 M | 258 M | 258 M | 258 M | 233 M | 233 M | 233 M | 233 M | 200 M | 200 M | 200 M | 200 M | 69.9 M | 69.9 M | 69.9 M | 69.9 M | 52.1 M | 52.1 M | 52.1 M | 52.1 M | 32.8 M | 36.5 M | 36.5 M | 36.5 M | 33.2 M | 7.7 M | 7.7 M | 7.7 M | 35 M | 2.21 M | 2.21 M | 2.21 M | 36 M | -6.68 M | -2 M | -2 M | 33.1 M | -69.8 M | -69.8 M | -69.8 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.31 B | -69.8 M | 266 M |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Brainsway Ltd.
BWAY
|
75.7 M | $ 22.96 | -0.56 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
1.85 B | $ 23.25 | -0.66 % | $ 250 M |  China |
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M |  USA |
 |
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
BioNano Genomics
BNGO
|
35.4 M | $ 1.59 | -0.94 % | $ 2.02 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
86 M | $ 6.12 | - | $ 180 M | USA |
 |
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B |  Australia |
 |
Castle Biosciences
CSTL
|
456 M | $ 39.59 | -0.76 % | $ 1.1 B | USA |
 |
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
261 M | $ 17.02 | -1.16 % | $ 915 M | USA |
 |
Danaher Corporation
DHR
|
77.5 B | $ 237.64 | 1.12 % | $ 174 B | USA |
 |
Celcuity
CELC
|
116 M | $ 107.43 | 2.63 % | $ 4.24 B | USA |
 |
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | USA |
 |
DarioHealth Corp.
DRIO
|
96.4 M | $ 12.15 | -5.81 % | $ 345 M | Israel |
 |
Anixa Biosciences
ANIX
|
18.9 M | $ 3.41 | -0.29 % | $ 109 K | USA |
 |
DexCom
DXCM
|
2.07 B | $ 66.95 | -2.16 % | $ 25.8 B | USA |
 |
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
QIAGEN N.V.
QGEN
|
6.15 B | $ 48.32 | -0.27 % | $ 10.8 B |  Niderland |
 |
Exact Sciences Corporation
EXAS
|
2.4 B | $ 102.13 | 0.34 % | $ 18.9 B | USA |
 |
Fulgent Genetics
FLGT
|
1.13 B | $ 27.84 | -0.2 % | $ 842 M | USA |
 |
Aspira Women's Health
AWH
|
6.73 M | - | -6.19 % | $ 10.5 M | USA |
 |
Guardant Health
GH
|
-140 M | $ 110.18 | 1.32 % | $ 13.5 B | USA |
 |
Charles River Laboratories International
CRL
|
3.51 B | $ 220.64 | 2.38 % | $ 11.3 B | USA |
 |
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
6.3 B | $ 141.01 | -3.31 % | $ 22.4 B | USA |
 |
IQVIA Holdings
IQV
|
6.07 B | $ 243.33 | 0.06 % | $ 44.1 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 175.1 | -1.49 % | $ 19.4 B | USA |
|
Biodesix
BDSX
|
20.9 M | $ 5.46 | -2.15 % | $ 708 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.07 B | $ 252.61 | -0.81 % | $ 21.2 B | USA |
 |
ICON Public Limited Company
ICLR
|
9.52 B | $ 183.13 | -2.7 % | $ 15.1 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.6 B | $ 715.47 | 0.43 % | $ 59 B | USA |
 |
Lantheus Holdings
LNTH
|
1.09 B | $ 67.98 | 0.19 % | $ 4.7 B | USA |
 |
Agilent Technologies
A
|
5.39 B | $ 148.92 | 2.17 % | $ 45.3 B | USA |
 |
Biomerica
BMRA
|
4.1 M | $ 2.75 | -4.84 % | $ 6.32 M | USA |
 |
Bioventus
BVS
|
221 M | $ 8.02 | 0.25 % | $ 502 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
12 B | $ 29.59 | 0.54 % | $ 20 B | Niderland |
 |
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | Israel |
 |
Precipio
PRPO
|
14.4 M | $ 24.77 | 7.28 % | $ 32.1 M | USA |
 |
Mettler-Toledo International
MTD
|
-127 M | $ 1 486.09 | 1.43 % | $ 31.5 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
701 M | $ 6.53 | -0.53 % | $ 592 M | USA |
 |
ENDRA Life Sciences
NDRA
|
2.56 M | $ 4.6 | -0.44 % | $ 2.47 M | USA |